MX2015015178A - Metodos para potenciar la regeneracion de musculos envejecidos. - Google Patents

Metodos para potenciar la regeneracion de musculos envejecidos.

Info

Publication number
MX2015015178A
MX2015015178A MX2015015178A MX2015015178A MX2015015178A MX 2015015178 A MX2015015178 A MX 2015015178A MX 2015015178 A MX2015015178 A MX 2015015178A MX 2015015178 A MX2015015178 A MX 2015015178A MX 2015015178 A MX2015015178 A MX 2015015178A
Authority
MX
Mexico
Prior art keywords
methods
enhancing
muscle regeneration
aged muscle
beta
Prior art date
Application number
MX2015015178A
Other languages
English (en)
Spanish (es)
Inventor
Sean Garvey
Suzette Pereira
Neile Edens
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2015015178A publication Critical patent/MX2015015178A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pediatric Medicine (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015015178A 2013-05-01 2014-05-01 Metodos para potenciar la regeneracion de musculos envejecidos. MX2015015178A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818237P 2013-05-01 2013-05-01
PCT/US2014/036297 WO2014179526A1 (en) 2013-05-01 2014-05-01 Methods for enhancing aged muscle regeneration

Publications (1)

Publication Number Publication Date
MX2015015178A true MX2015015178A (es) 2016-02-26

Family

ID=50885012

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015178A MX2015015178A (es) 2013-05-01 2014-05-01 Metodos para potenciar la regeneracion de musculos envejecidos.

Country Status (11)

Country Link
US (1) US20160066610A1 (enExample)
EP (1) EP2999359A1 (enExample)
JP (1) JP2016520050A (enExample)
CN (1) CN105188413A (enExample)
BR (1) BR112015027563A2 (enExample)
CA (1) CA2911471A1 (enExample)
HK (1) HK1221609A1 (enExample)
MX (1) MX2015015178A (enExample)
PH (1) PH12015502319A1 (enExample)
SG (1) SG11201508388YA (enExample)
WO (1) WO2014179526A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015094772A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for increasing skeletal muscle protein synthesis using green tea extract
WO2016044272A1 (en) * 2014-09-16 2016-03-24 Abbott Laboratories Methods of preserving muscle strength during a period of muscle disuse by administering beta-hydroxy-beta-methylbutyrate and green tea extract
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
US10596138B2 (en) 2015-09-16 2020-03-24 Abbott Laboratories Reduced fat, shelf stable liquid nutritional composition
WO2017123922A1 (en) * 2016-01-13 2017-07-20 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) FOR JOINT STABILITY
ES2811378T3 (es) * 2016-04-01 2021-03-11 Dsm Ip Assets Bv Bebidas que comprenden gránulos estables de luteína molida
MX2018014407A (es) 2016-05-25 2019-02-21 Tsi Group Ltd Estabilizacion de formulaciones de acido beta-hidroxiisovalerico en capsulas de gel blando.
US20210368843A1 (en) * 2016-08-04 2021-12-02 Seattle Gummy Company Mineral compositions and methods of making and using thereof
CN109661180A (zh) * 2016-08-04 2019-04-19 西雅图咖米公司 用于运动成绩的组合物及其制造和使用方法
WO2018027081A1 (en) * 2016-08-04 2018-02-08 Seattle Gummy Company Health management compositions and methods of making and using thereof
EP3528801B1 (en) 2016-10-21 2024-07-17 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) and probiotics
US12370159B2 (en) 2016-10-21 2025-07-29 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics
BR112019023794A2 (pt) 2017-06-09 2020-06-02 Philip Morris Products S.A. Artigo gerador de aerossol com segmento de filtro fibroso
US20190037904A1 (en) * 2017-08-04 2019-02-07 Sean R. Daly Food-based protein formulation
MX392627B (es) * 2018-02-09 2025-03-24 Haldor Topsoe As Proceso de produccion de compuestos de alfa-hidroxi y usos de los mismos
CN112312772A (zh) * 2018-06-23 2021-02-02 西雅图咖米公司 用于降低咖啡因副作用的方法和组合物
JP6541047B1 (ja) * 2018-10-18 2019-07-10 株式会社東洋新薬 経口組成物
CA3175049A1 (en) * 2020-03-10 2021-04-15 The Regents Of The University Of California Novel nutrients to enhance load-induced muscle hypertrophy
WO2021236440A1 (en) 2020-05-20 2021-11-25 Advanced Food Concepts, Inc. Athletic performance enhancement composition using menthol
CN112568444A (zh) * 2020-11-20 2021-03-30 格乐瑞(无锡)营养科技有限公司 一种缓解肌肉流失的组合物及其制备方法
WO2023190293A1 (ja) * 2022-03-30 2023-10-05 ニュートリー株式会社 とろみ状栄養組成物
WO2025030001A2 (en) * 2023-08-02 2025-02-06 Abbott Laboratories Methods and compositions for maintaining skeletal muscle mobility and/or mass, and/or for recovery of skeletal muscle strength

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445807B2 (en) * 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
ATE508745T1 (de) * 2005-11-30 2011-05-15 Novartis Pharma Gmbh Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund
WO2007116962A1 (ja) * 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
JP5507802B2 (ja) * 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
EP3231435A1 (en) * 2009-07-20 2017-10-18 Nestec S.A. Methods of attenuating the loss of functional status
CA2821312A1 (en) * 2010-12-27 2012-07-05 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
WO2012097061A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose

Also Published As

Publication number Publication date
EP2999359A1 (en) 2016-03-30
CN105188413A (zh) 2015-12-23
PH12015502319A1 (en) 2016-02-10
CA2911471A1 (en) 2014-11-06
JP2016520050A (ja) 2016-07-11
SG11201508388YA (en) 2015-11-27
HK1221609A1 (zh) 2017-06-09
US20160066610A1 (en) 2016-03-10
BR112015027563A2 (pt) 2017-07-25
WO2014179526A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
PH12015502319A1 (en) Methods for enhancing aged muscle regeneration
IL240488A0 (en) Vaccine preparation for mers corona virus infection
MX359327B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
PH12015501354A1 (en) Antiviral compounds
UY34804A (es) Inhibidores del nampt
UY34697A (es) Métodos para preparar análogos de nucleótidos
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
PH12015502167A1 (en) Methods of maintaining and improving muscle function
ZA201707183B (en) Regenerative railway braking system
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
SG11201502649WA (en) Methods for enhancing the effect of egcg on mitigating skeletal muscle loss
MX2015015593A (es) Placa de osteosintesis y sistema para osteosintesis.
MY173521A (en) Trpv4 antagonists
MX2014015390A (es) Metodos para la desolventizacion de bagazo.
EP2989123A4 (en) METHODS AND COMPOSITIONS FOR TREATING COAGULATION DISORDERS
WO2014091167A3 (fr) Composes cyclopropylboroniques, leur procede de preparation et leur utilisation
WO2015011669A3 (en) Phenolic compounds as end-capping agents for polysiloxanes in polycarbonate-polysiloxane block copolymers
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
SG11201500918YA (en) Method, combination and/or composition for inducing cardiomyocyte differentation
IN2014DN09584A (enExample)
PH12015501281B1 (en) Use of methyl mercapto-esters as chain transfer agents